Skip to main content
Premium Trial:

Request an Annual Quote

Strategic Diagnostics Joins Delaware Collaboration to Find Prostate Cancer Biomarkers

NEW YORK (GenomeWeb News) – Strategic Diagnostics will collaborate with the University of Delaware and the Helen F. Graham Cancer Center to develop protein biomarkers that could be used to detect metastasis in prostate cancer patients, the company said on Thursday.
 
SDI said it will work with UD to develop antibodies that identify protein molecule fragments that break away from primary tumors when cancer is spreading. Diagnostic tests using these antibodies could help doctors determine the stage and the severity of the cancer, and could help them develop effective treatment options specifically for metastasized cancer cases.
 
SDI President and CEO Francis DiNuzzo said in a statement that the company will use its Genomic Antibody Technology to develop the biomarker tests.
 
Further terms of the alliance were not disclosed.
 
The Helen F. Graham Cancer Center is one of 14 National Cancer Institute centers in the US.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.